Biotech Co.*

Pharma Co.

Type/Product Area

Terms/Details (Date)


bioMerieux SA (France)

bioMerieux gained long-term and comprehensive access to Affymetrix's GeneChip technology

bioMerieux will use the technology for in vitro diagnostic tests for breast cancer; it also got an option to expand the deal into other cancer areas; terms were not disclosed (4/5)


Beijing Double-Crane Pharmaceutical Co. Ltd. (China)

They entered a memorandum of understanding on a deal to develop Oxygent in China

Alliance would be entitled to up-front, milestone and royalty payments if a license deal is executed (4/5)

Group plc*

Boehringer Ingelheim International GmbH (Germany)

BI got rights to use Ark renin-angiotensin system technologies in its products

Ark gets an up-front payment and could receive milestone payments and royalties on sales of cardiovascular products covered by its patents (4/1)


Novartis AG (Switzerland)

Worldwide deal to develop small-molecule drugs targeting macrophage migration inhibitory factor for treating inflammatory diseases

Avanir is eligible to receive more than $200M in up-front and development, regulatory and sales milestone payments, and gets up to $2.5M per year for four years in research payments; it also would get royalties on sales (4/28)

BioCurex Inc.

Abbott Laboratories

Abbott licensed RECAF technology, a cancer biomarker that may be useful in new diagnostic tests

BioCurex gets up-front fees, development milestones and royalties on any sales; Abbott gets worldwide, semi-exclusive rights (3/29)

BioFocus plc

Eli Lilly and Co.

Deal to discover compounds that target nuclear hormone receptors

The deal involves use of BioFocus' high- throughput expertise; BioFocus will get research fees that increase as the program progresses (3/2)

Biolex Inc.*

Centocor Inc. (unit of Johnson & Johnson)

Deal under which Biolex will manufacture and help advance certain Centocor proteins using the Biolex LEX System

Biolex, which will advance up to 10 proteins, gets an up-front payment and potential milestones and royalties; it also gets funding over three years to support scale-up of parts of the system, and J&J will make an equity investment in Biolex's next financing (3/21)

Cangene Corp.
(Canada; TSE:CNJ)

Baxter Healthcare Corp.

Baxter assumed exclusive rights to market Cangene's WinRho SDF immune globulin product in the U.S.

Baxter already markets the product for immune thrombocytopenic purpura in the UK, and intends to launch it in 10 other European countries; terms were not disclosed (3/29)

Cellzome Inc.*

Ortho-McNeil Pharmaceutical Inc. (unit of Johnson & Johnson)

Collaboration to identify new medicines for treating Alzheimer's disease

Cellzome is providing access to its AD technology in exchange for a technology access fee and research funding for two years, as well as potential milestone and royalty payments (3/16)


Schering AG (Germany)

Research service agreement to accelerate Schering's target discovery and validation efforts

Cenix will validate collections of candidate genes identified by Schering as possible therapeutic drug targets; terms were not disclosed (2/28)

CepTor Corp.

JCR Pharmaceuticals Co. Ltd. (Japan)

JCR got a 15-year license to market CepTor's muscular dystrophy product Myodur in the Pacific Rim

The deal entitles CepTor to equity payments, milestone payments and double-digit royalties on sales in the Pacific Rim (3/2)


UCB Group SA (Belgium)

ChemBridge will provide chemistry services to help UCB discovery efforts

Further details and financial terms were not disclosed (3/2)

Group Inc.*

Pfizer Inc.

Worldwide deal to develop and sell Coley's ProMune, a Toll- ike receptor 9 agonist, for cancer indications

Coley gets $50M up front and up to $455M more in milestone payments, plus royalties on any sales; Pfizer may invest up to $10M in Coley upon Coley's initial public offering (3/24)


URL/Mutual Pharmaceutical Co.

Deal to develop and sell an undisclosed product

Collegium will do early work on the compound, then transfer responsibilities to URL; Collegium is entitled to milestone and royalty payments (4/20)

Compugen Ltd.
(Israel; CGEN)

Novartis AG (Switzerland)

Compugen will develop a platform for research and analysis of biological data on biological interaction networks

Novartis will make a one-time payment for the information, and get sole rights to the project results; Compugen retains rights to the research and discovery systems developed through the collaboration (4/19)

Crucell NV (the
Netherlands; CRXL)
and DSM Biologics
(the Netherlands)

Mitsubishi Pharma Corp. (Japan)

Mitsubishi got rights to use the PER.C6 cell line for producing certain recombinant therapeutic proteins

Mitsubishi will make an up-front payment and pay annual maintenance fees; further terms were not disclosed (3/23)

Crucell NV (the
Netherlands; CRXL)
and DSM Biologics
(the Netherlands)

JCR Pharmaceuticals Co. Ltd. (Japan)

JCR got rights to use the PER.C6 cell line for producing certain recombinant therapeutic proteins

JCR will make a research license payment and annual maintenance fees; further terms were not disclosed (3/10)

Cyclacel Group

Altana Pharma AG (Germany)

Cyclacel will use its expertise in cell division to identify molecular targets of specific Altana drug candidates

Terms of the deal were not disclosed (3/16)


Daiichi Pharmaceutical Co. Ltd. (Japan)

Daiichi will use Cyntellect's high-throughput cell-imaging and cell-manipulation technologies in drug discovery

Cyntellect will design and run LEAP cell- based assays against a Daiichi compound collection; terms of the deal were not disclosed (3/30)


DePuy Spine Inc. (unit of Johnson & Johnson)

Second deal between the companies gave DePuy rights to autologous platelet releasate therapy

The license excludes treatment of chronic wounds; also, DePuy's existing license for spinal, orthopedic and neurosurgical applications will be converted to a nonexclusive license; terms were not disclosed (3/8)

Depomed Inc.

Boehringer Ingelheim Pharmaceuticals Inc. (Germany)

Depomed will develop a controlled-release formulation of an undisclosed compound for BI

Depomed will apply its Gastric Retention technology to the BI compound; a license agreement could follow (4/28)


Undisclosed U.S. company

They signed a second deal in three months; Eiffel will use its re-engineering technology to formulate an asthma drug

Eiffel will receive a $75,000 up-front payment for the two-month study; further licensing deals could ensue (2/28)


Bristol-Myers Squibb Co.

Elixir got exclusive rights to BMS's growth hormone secretagogue BMS-604992 and five related compounds

BMS gets an up-front license fee comprised of cash and stock, and is entitled to milestone and royalty payments; the program is at the preclinical stage (4/28)


Novartis Pharma AG (Switzerland)

Collaboration for drug discovery in the area of receptor tyrosine kinase inhibitors

Novartis gets nonexclusive access to ESBA- Tech's cellular high-throughput technology under undisclosed terms (3/31)

Evotec OAI

Mitsubishi Pharma Corp. (Japan)

Evotec will support the advancement of compound hit series for Mitsubishi drug targets

Terms of the medicinal chemistry agreement were not disclosed (2/28)


Schwarz Pharma AG (Germany)

Collaboration to develop hits against targets that they identified in a pilot project

4SC will use its technologies to develop pharmaceutical leads; 4SC gets research funding and is entitled to milestone payments and revenue sharing (4/5)

GeneGo Inc.*

NV Organon (the Netherlands)

Organon licensed GeneGo's MetaCore platform for mining high-throughput experimental data

Organon will use MetaCore in preclinical research across various therapeutic areas (4/19)

Gene Network

Johnson & Johnson Pharmaceutical Research & Development LLC

GNS will provide pathway inference technology and data- driven computer modelsto J&J

The technology will help determine pathways data for a J&J preclinical oncology compound; terms of the deal were not disclosed (3/7)


Ipsen SA (France)

Deal to develop sustained- release formulations of Genentech's recombinant human growth hormone

The alliance supplements an existing deal under which Ipsen markets NutropinAq in Europe and has rights elsewhere except North America and Japan; terms of the deal were not disclosed (3/21)


bioMerieux SA (France)

Genome Express will carry out bacterial analyses for bioMerieux

Terms of the deal were not disclosed (3/4)

Biotech Inc.*

Beckman Coulter Inc.

BC got access to GenWay's IgY microbead technology, which can be used in detecting biomarkers and drug targets

The exclusive license agreement also provides a basis for future collaboration on development of GenWay's IgY capture technology; terms were not disclosed (3/31)

Sciences Inc.

Japan Tobacco Inc. (Japan)

Gilead got exclusive rights outside Japan to develop an HIV integrase inhibitor (JTK-303)

JT gets $15M up front and up to $90M in milestone payments, as well as royalties on any sales; Gilead plans to start Phase I/II trials by mid-2005 (3/22)

BioPharma Corp.
(Canada; TSE:HBP)

Apotex Group (Canada)

Helix will identify and characterize a lead formulation for Apotex's topical therapeutic product line

The work will be done by Helix subsidiary PharmaDerm Laboratories; terms were not disclosed (2/28)


Roche Diagnostics (Switzerland)

Collaboration to analyze patient samples for discovery of cancer biomarkers

IGC gets access to certain gene-expression data and support for further biological characterization of the samples in Iceland; terms of the deal were not disclosed (3/17)

Icoria Inc.

Syngenta Ltd.

Syngenta got exclusive rights to develop 30 Icoria compounds believed to be active fungal inhibitors

Syngenta will evaluate the compounds over 18 months, then could develop them in agricultural, human and other applications; Icora gets an up-front payment and could receive milestone and royalty payments (2/28)


Reckitt Benckiser Healthcare (UK)

Collaboration on Ionix's IX- 003 for post-operative pain and the preclinical products IX- 004 and IX-1005, for pain and opiate addiction

All three products are based on intranasal delivery of RBH's buprenorphine; Ionix is eligible for milestone and royalty payments, and retains an option to co-promote IX-1003 in the U.S. (2/28)

Intercell AG

Biological E. Ltd. (India)

Deal under which Biological E. will manufacture and sell Intercell's Japanese encephalitis vaccine in Asia

The companies said they intend to work together in the future on other vaccines; terms were not disclosed (3/18)

KineMed Inc.*

Sosei Co. Ltd. (Japan)

KineMed will screen a number of Sosei molecules to determine their potential in new indications

KineMed will use its in vivo KineMarker assays in the deal, terms of which were not disclosed (4/13)


Pfizer Inc.

Deal to develop an automated pathology system for evaluation of tissue specimens in preclinical studies

The system developed by LifeSpan uses enhanced image capture and artificial intelligence computer analysis software; terms were not disclosed (3/3)


Scios Inc. (unit of Johnson & Johnson)

Deal under which Locus will apply its molecular fragment technology focused on protein kinases

Locus will design for Scios new chemical classes of protein kinase inhibitors under undisclosed terms (3/14)


Sumitomo Pharmaceuticals Co. Ltd. and Koken Co. Ltd. (both Japan)

Deal to develop Lorus' antisense cancer drug GTI-2601 with the partners' collagen-based delivery system

The companies will jointly own resulting compounds; terms of the deal were not disclosed (4/5)


Abbott Laboratories

Abbott will market Numax, MedImmune's anti-RSV monoclonal antibody in Phase III trials, outside the U.S.

Abbott also will continue to market Synagis under the amended deal; MedImmune has the option to co-promote Numax in up to seven countries outside the U.S.; it retained rights in the U.S. (2/28)

Pte. Ltd.*

Sankyo Co. Ltd. (Japan)

Three-year collaboration under which MerLion will isolate new drug leads for Sankyo

Sankyo would develop and commercialize resulting products; terms of the deal were not disclosed (4/20)


Boehringer Ingelheim GmbH (Germany)

An expanded collaboration gives BI an option to several exclusive licenses on new therapeutic antibody programs

They already are developing two antibody programs; BI also got access to MorphoSys' HuCAL Gold library; MorphoSys gets a technology access fee, annual license fees and optional R&D funding over five years, as well as potential milestones and royalties (3/17)


BioGeneriX AG (Germany; part of the Ratiopharm Group)

License and option deal to use Neose's GlycoPEGylation technology to develop a long-acting form of a marketed therapeutic protein

The deal follows a previous supply and option agreement; Neose will get further up-front and research payments, and could get up to $61.5M in milestone payments, as well as royalties on any sales (4/28)

Novavax Inc.

Ranbaxy Laboratories Inc. (India)

Deal to evaluate a transdermal product formulated using Novavax's micellar nanoparticle technology

Novavax will get funding to complete a proof-of-concept study, which could be followed by a commercialization and development agreement (3/16)


Novo Nordisk A/S (Denmark)

Collaboration to discover drug leads for targets provided by Novo

Nuevolution will use its Chemetics technology in the effort; terms of the deal were not disclosed (4/12)

Nuvelo Inc.

Kirin Brewery Co. Ltd. (Japan)

Collaboration to advance the preclinical growth factor NU206, which was developed under an existing alliance

Nuvelo will lead development; it gets a $2M up-front payment, and will pay 60% of the costs and get 60% of the revenues from the program (4/4)

Osel Inc.*

Miyarisan Pharmaceutical Co. Ltd. (Japan)

Osel gained exclusive rights in North America and Europe to MIYA-BM

The oral product is approved in Japan for treating antibiotic-induced gastrointestinal disorders; terms of the deal were not disclosed (3/2)

Oxford Genome
Sciences Ltd.*

Bayer HealthCare AG (Germany)

Oxford will evaluate candidate biomarkers that may have applications in breast cancer

Oxford gets funding for the program under which it will apply proteomics technologies, and potential milestone payments (3/16)

Pepscan Systems
of the Netherlands)

Solvay Pharmaceuticals (Belgium)

The companies will identify novel peptide substrates for a series of Solvay proteases

Terms of the research agreement for the de-orphanization of proteases were not disclosed (3/8)

Sciences Inc.*

Mitsubishi Pharma Corp. (Japan)

Perlegen got rights outside of Asia to the PPAR agonist, MCC-555, a product in the clinic for treating diabetes and other metabolic disorders

Mitsubishi gets an up-front payment and could receive cash and equity milestone payments; it also gets rights to use predictive genetic markers identified by Perlegen; they each would pay royalties on sales (4/12)


Novartis AG (Switzerland)

Novartis licensed a GPCR peptide ligand library designed by PDI

Terms of the deal were not disclosed (4/20)

Proteolab AG*

Syngenta AG (Switzerland)

Collaboration to develop an anticalin-based drug from Pieris for an undisclosed indication

Pieris is responsible for research and for providing the active drug; Syngenta is responsible for development and commercialization; terms were not disclosed (4/13)

Power3 Medical Products Inc. (OTC BB:PWRM)

New Horizons Diagnostics Corp.

Collaboration to develop antibody-based diagnostics for neurodegenerative diseases

The work will involve protein biomarkers from Power3; terms of the deal were not disclosed (3/28)

Biopharma Inc.
(Canada; TSE:PBP)

Medicorp Inc. (Canada)

Medicorp got exclusive rights to develop and sell PSP94-based test kits

Medicorp will fund future development; they will share revenues from sales of test kits, and from sublicensing deals (3/2)

Regenera Ltd.

Alcon Manufacturing Ltd.

Alcon licensed a product used to assist in visualization of vitreous fluid during a vitrectomy

Regenera gets an up-front payment and is entitled to milestone and royalty payments (double-digit in the U.S.) (4/7)


Ferring Holding SA (Switzerland)

They entered a co-promotion deal on Nuflexxa as part of Savient's divestiture of its global biologics manufacturing business to Ferring

Savient will establish a sales force for the co-promotion effort, and get 50% of the global revenue from the approved sodium hyaluronate product above certain revenue thresholds; Ferring is paying $80M in cash over two years for the manufacturing busi- ness (3/23)

Senetek plc

Signet Laboratories Inc.

They finalized a deal under which Signet will manufacture and market monoclonal antibodies licensed to Senetek

Signet will get a share of the revenues; the deal finalizes an amendment to an April 2004 deal (4/7)

Serono SA

Rosetta Biosoftware (unit of Merck & Co. Inc.)

Serono licensed use of the Rosetta Resolver system

Serono gets rights to the gene-expression data analysis system under undisclosed terms (2/28)

7TM Pharma

Procter & Gamble Pharmaceuticals Inc.

Collaboration to research the use of therapeutic angiogenesis to identify candidates for treating vascular diseases

P&G got exclusive rights to molecules derived from the program in exchange for an up-front fee, potential milestone payments and royalties on any sales; 7TM retained co-promotion rights in Scandinavia (4/12)


Mundipharma International Holdings Ltd. (UK)

Deal under which Mundipharma will market and distribute DepoBupivacaine in Europe and elsewhere excluding the U.S., Canada and Japan

SkyePharma gets $10M up front and up to $20M toward Phase III trials; it also is entitled to development and sales milestones that could bring total payments to $80M; SkyePharma would get 30% to 35% of sales, out of which it would pay for manufacturing (4/19)


Bristol-Myers Squibb Co.

Sunesis licensed all rights to the cancer drug BMS-387032 (now SNS-032), a cyclin-dependent kinase inhibitor, and any related compounds

BMS gets an up-front equity stake of $8M in Sunesis, and up to $29M in cash and equity milestone payments for the first approval; other milestones could total $49M million; BMS also would get royalties on sales (4/28)


Bioaccelerate Holdings Inc.

Worldwide license and co-marketing deal for IoGen, a Symbollon product for treating cyclic mastalgia

Bioaccelerate will fund ongoing Phase III development, and would commercialize the product; they would share any resulting profits (4/13)


GlaxoSmithKline plc (UK)

GSK exercised its option to license Theravance's inhaled bifunctional, muscarinic antagonist/beta2 agonist program

Theravance could get up to $252M in up- front and milestone payments, if the program has both single-agent and combina- tion products; it is the third respiratory program GSK licensed from Theravance (3/21)


Eisai Co. Ltd. (Japan)

They entered a research agreement involving drug discovery for Alzheimer's disease

Eisai has exclusive rights of first negotiation for validated compounds discovered through the research; development deals could follow (3/18)

Therapies Inc.

Shire Pharmaceuticals Group plc (UK)

Shire got rights to manufacture and distribute Dynepo outside of North America

The license will take effect only if Shire's planned $1.6B acquisition of TKT does not occur for specified reasons (4/21)

Vectura Group
and Arakis Ltd.*

Novartis AG (Switzerland)

Novartis gained rights to the two companies' AD 237, as a monotherapy and with up to $172.5M in milestone payments, as QAB149, for treating chronic obstructive pulmonary disease

Arakis and Vectura each will get $15M up front; they each also are eligible to receive well as royalties on any sales (4/13)


Wyeth Pharmaceuticals

VirtualScopics will provide analytical and other imaging services to Wyeth

The services will be used in a Phase I trial of a product being studied for muscle wasting conditions; terms were not disclosed (3/14)

Xencor Inc.*

Eli Lilly and Co.

Lilly exercised its option under a February 2004 deal to develop one or more proteins created by Xencor

Xencor gets an up-front license fee and is eligible to receive milestone payments, as well as royalties on any sales (4/13)

Xenova Group

PharmaEngine Inc. (Taiwan)

PharmaEngine licensed rights to the brain cancer product TransMID in China and South Korea

Xenova gets an up-front payment, as well as potential milestone payments and royalties on any sales; it also will supply the product (4/13)


Wyeth Pharmaceuticals

Three-year expansion of an alliance to develop gap junction-modifying drugs for cardiovascular diseases

The alliance followed a 2003 license deal for the co- development of ZP123, a drug being developed for arrhythmias; they now will work on other compounds, and Wyeth got rights to evaluate Zealand's compound library; terms were not disclosed (3/4)


# The information in the chart does not cover agricultural agreements or those between biotech companies.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; ATX = Austrian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.